|
Gene: SNTB2 |
Gene summary for SNTB2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SNTB2 | Gene ID | 6645 |
Gene name | syntrophin beta 2 | |
Gene Alias | D16S2531E | |
Cytomap | 16q22.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024R732 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6645 | SNTB2 | ATC5 | Human | Thyroid | ATC | 8.12e-51 | 1.14e+00 | 0.34 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SNTB2 | SNV | Missense_Mutation | c.1000G>A | p.Glu334Lys | p.E334K | Q13425 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
SNTB2 | SNV | Missense_Mutation | c.1516C>T | p.Pro506Ser | p.P506S | Q13425 | protein_coding | tolerated(0.08) | possibly_damaging(0.576) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SNTB2 | SNV | Missense_Mutation | c.1442A>G | p.Tyr481Cys | p.Y481C | Q13425 | protein_coding | deleterious(0.03) | possibly_damaging(0.808) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
SNTB2 | SNV | Missense_Mutation | rs201410231 | c.1589N>T | p.Ser530Leu | p.S530L | Q13425 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SNTB2 | SNV | Missense_Mutation | c.1376T>G | p.Leu459Arg | p.L459R | Q13425 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
SNTB2 | SNV | Missense_Mutation | c.914A>C | p.Gln305Pro | p.Q305P | Q13425 | protein_coding | deleterious(0.04) | possibly_damaging(0.51) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SNTB2 | insertion | Frame_Shift_Ins | novel | c.748dupA | p.Met250AsnfsTer6 | p.M250Nfs*6 | Q13425 | protein_coding | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | ||
SNTB2 | SNV | Missense_Mutation | c.1521N>T | p.Glu507Asp | p.E507D | Q13425 | protein_coding | tolerated(0.2) | probably_damaging(0.996) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
SNTB2 | SNV | Missense_Mutation | c.1450N>G | p.Pro484Ala | p.P484A | Q13425 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-D1-A16B-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SNTB2 | SNV | Missense_Mutation | novel | c.1543N>T | p.His515Tyr | p.H515Y | Q13425 | protein_coding | deleterious(0.02) | probably_damaging(0.974) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |